Finding comparable safety and immunogenicity in U.S. and Ugandan populations provided proof of principle that a protective, multivalent filovirus vaccine is attainable.
For the published broad agency announcement, see the April 29, 2016 solicitation, Advanced Development of Multivalent Vaccine Candidates for Filovirus and Lassa Fever.